Today

Sysco announced a definitive agreement to acquire Jetro Restaurant Depot for $21.6 billion in cash and 91.5 million shares of HoldCo Common Stock, with Jetro equityholders expected to hold approximately 16% of the combined entity.

Accelerate Diagnostics' common stock will be delisted from Nasdaq effective May 15, 2025, following its Chapter 11 bankruptcy filing and failure to meet minimum bid price requirements.

Carver Bancorp is voluntarily delisting from Nasdaq and moving to the OTCQX Market, with trading expected to commence on December 8, 2025.

T2 Biosystems' common stock will be delisted from Nasdaq and trading suspended effective February 12, 2025, with no further appeal planned, and will transition to OTC Markets.

Cutera Inc.'s common stock will be delisted from Nasdaq and suspended from trading on March 13, 2025, following the company's Chapter 11 bankruptcy filing.

Cutera will voluntarily delist its common stock from Nasdaq, effective around March 30, 2025, due to its Chapter 11 bankruptcy filing.

TuSimple Holdings Inc. is voluntarily delisting its common stock from Nasdaq and terminating its SEC registration, impacting trading access and liquidity.

Erayak Power shareholders approved a massive increase in authorized shares and a flexible reverse stock split, indicating potential future capital raises and share price adjustments.

Baiya International Group will implement a 1-for-25 reverse stock split to maintain its Nasdaq listing.

Synlogic's common stock was suspended from Nasdaq trading on January 21, 2026, after the company withdrew its appeal against delisting.

Synlogic's common stock will be suspended from Nasdaq trading on January 21, 2026, after the company withdrew its appeal against delisting.

River Financial Corp confirmed data removal in a cybersecurity incident and now faces two class action lawsuits, increasing legal risk.

River Financial Corporation disclosed a ransomware attack that affected its network and operations, with the full impact still under investigation.

Hawaiian Electric reached a definitive $1.99 billion settlement for Maui wildfire tort claims, reducing significant legal and financial uncertainty.

Equinix is facing an independent investigation by its Audit Committee and a federal subpoena related to a short seller report.

Outlook Therapeutics' appeal for its nAMD treatment, ONS-5010/LYTENAVA™, has been granted by the FDA, paving the way for a BLA resubmission.

Arvinas received FDA approval for VEPPANU, its lead PROTAC drug for advanced breast cancer, triggering a $50 million milestone payment.

Capricor Therapeutics announced an FDA Advisory Committee meeting for its Duchenne muscular dystrophy therapy, Deramiocel, ahead of an August PDUFA date.

Ultragenyx's gene therapy for GSDIa received FDA Priority Review, setting an August 2026 action date.

Ultragenyx received FDA clearance for its IND application for UX016, enabling a Phase 1/2 study for GNE myopathy.